New York – February 27, 2019 – Creative Biolabs, an antibody provider located in New York, now offers a comprehensive list of recombinant antibodies for the post-translational modification research.
Post-translational modification (PTM) occurs on a protein, catalyzed by enzymes after the translation is completed by ribosomes, which controls a variety of cellular activities, such as regulating the folding of proteins, their targeting to specific subcellular compartments, their interaction with ligands or other proteins, and their functional state. However, PTM research is hampered by the lack of specific reagents due in large part to their ubiquitous and non-immunogenic nature. Therefore, Creative Biolabs now releases anti-AKT1 antibody and NFKBIA antibody to support PTM research.
anti-AKT1 antibody, referring to the antibody that targets to AKT1 that is a critical mediator of growth factor-induced neuronal survival in the developing nervous system, can react with mouse, rat, and human, can be applied to immunoassays such as ELISA, WB, and used for detecting phosphorylation and non-phosphorylation of serine in AKT1. The serine-threonine protein kinase encoded by the AKT1 gene is catalytically inactive in serum-starved primary and immortalized fibroblasts. AKT1 and the related AKT2 are activated by platelet-derived growth factor. The activation is rapid and specific, and it is abrogated by mutations in the pleckstrin homology domain of AKT1.
NFKBIA antibody is another common antibody in PTM research for immunoassays, such as ICC/IF, WB, IHC-P, IP, Flow Cyt. It can react with human, mouse, rat, pig, cattle, and dog, and detect the phosphorylation and non-phosphorylation of serine in NFKBIA. The encoded protein interacts with REL dimers to inhibit NF-kappa-B/REL complexes which are involved in inflammatory responses and moves between the cytoplasm and the nucleus via a nuclear localization signal and CRM1-mediated nuclear export. On cellular stimulation by immune and proinflammatory responses, NFKBIA antibody becomes phosphorylated promoting ubiquitination and degradation, to enable the dimeric RELA to translocate to the nucleus and activate transcription.
As a leading manufacturer with extensive experience in antibody production and engineering, Creative Biolabs has been dedicated to discovering and manufacturing recombinant antibodies for more than ten years. Up to now, a comprehensive antibody library has been developed for the application of tumor marker detection, tissue imaging, cell & organelle imaging, diagnostic support, activators & inhibitors, isotype & loading controls. If you need more information on specific antibodies, please visit https://www.antibody-creativebiolabs.com.
About Creative Biolabs
Since 2004, Creative Biolabs has been dedicated to providing high-quality services to the academic and life sciences worldwide. In the past decade, Creative Biolabs become the leader in the discovery and manufacture of recombinant antibodies. A custom-service-centered business model is crucial for optimizing the drug development process, leveraging accessible resources, and gathering a team from various backgrounds to conduct drug discovery projects in the future. As the preferred supplier for global customers, scientists in Creative Biolabs are confident to provide customers with first-class services covering a full range of applications.
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Address:45-1 Ramsey Road
State: New York
Country: United States